GRACEcast
Howard (Jack) West, MD
1 Listener
All episodes
Best episodes
Top 10 GRACEcast Episodes
Goodpods has curated a list of the 10 best GRACEcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to GRACEcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite GRACEcast episode by adding your comments to the episode page.
07/02/13 • 4 min
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
1 Listener
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
1 Listener
Could BRAF be a new target in NSCLC?
GRACEcast
06/27/13 • 4 min
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.
1 Listener
12/06/13 • 11 min
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio)
GRACEcast
09/28/13 • 8 min
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.
Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio)
GRACEcast
09/28/13 • 6 min
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Show more best episodes
Show more best episodes
FAQ
What is the most popular episode on GRACEcast?
The episode title 'Can we target KRAS effectively in advanced NSCLC?' is the most popular.